Newron Pharmaceuticals S.p.A. NWRN-Financial and Strategic SWOT Analysis Review

Newron Pharmaceuticals S.p.A. NWRN-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH82486FSA
  • |
  • Pages: 42
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Newron Pharmaceuticals S.p.A. (NWRN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Newron Pharmaceuticals S.p.A (Newron) is a research-based biopharmaceutical company which focuses on the discovery, development and commercialization of novel therapeutic drugs for the treatment of central nervous system disorders and pain. The company's marketed product, Xadago (safinamide), is developed as an adjunctive therapy for any stage of Parkinson's disease. Newron's other products in pipeline include ralfinamide for neuropathic pain; sarizotan for Rett syndrome; and NW-3509 for the treatment of schizophrenia. The company has development and commercialization collaborations with Zambon and Meiji Seika Pharma Co., Ltd. It operates along with its subsidiaries in the UK, Sweden, Switzerland and the US. Newron is headquartered in Bresso, Milan, Italy.

Newron Pharmaceuticals S.p.A. Key Recent Developments

Sep 15, 2015: Newron Reports Half-Year 2015 Results

Mar 04, 2015: Newron Pharmaceuticals Reports 2014 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Section 1-About the Company 6

Newron Pharmaceuticals S.p.A.-Key Facts 6

Newron Pharmaceuticals S.p.A.-Key Employees 7

Newron Pharmaceuticals S.p.A.-Key Employee Biographies 8

Newron Pharmaceuticals S.p.A.-Major Products and Services 9

Newron Pharmaceuticals S.p.A.-Pharmaceutical Pipeline Products Data 10

Newron Pharmaceuticals S.p.A., Pipeline Products by Therapy Area 10

Newron Pharmaceuticals S.p.A., Pipeline Products by Development Phase 11

Newron Pharmaceuticals S.p.A.-History 13

Newron Pharmaceuticals S.p.A.-Company Statement 17

Newron Pharmaceuticals S.p.A.-Locations And Subsidiaries 19

Head Office 19

Other Locations & Subsidiaries 19

Section 2-Company Analysis 20

Newron Pharmaceuticals S.p.A.-Business Description 20

Newron Pharmaceuticals S.p.A.-Corporate Strategy 21

Newron Pharmaceuticals S.p.A.-SWOT Analysis 22

SWOT Analysis-Overview 22

Newron Pharmaceuticals S.p.A.-Strengths 22

Strength-Focused Research and Development Actibvities 22

Strength-Strategic Alliances 22

Strength-Lead Product: Xadago 22

Newron Pharmaceuticals S.p.A.-Weaknesses 23

Weakness-History of Operating Losses 23

Weakness-Termination of Projects 23

Newron Pharmaceuticals S.p.A.-Opportunities 24

Opportunity-Strong Product Pipeline 24

Opportunity-Growing Market for Orphan Drugs 24

Opportunity-Domestic Expansion 24

Opportunity-Response Letter Delays Approval of Xadago 24

Newron Pharmaceuticals S.p.A.-Threats 25

Threat-Intense Competition 25

Threat-Product Liability Claims 25

Threat-Government Regulations 25

Newron Pharmaceuticals S.p.A.-Key Competitors 26

Section 3-Company Financial Ratios 27

Financial Ratios-Capital Market Ratios 27

Financial Ratios-Annual Ratios 28

Performance Chart 29

Financial Performance 29

Financial Ratios-Interim Ratios 30

Financial Ratios-Ratio Charts 31

Section 4-Company's Lifesciences Financial Deals and Alliances 32

Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 32

Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 33

Newron Pharmaceuticals S.p.A., Recent Deals Summary 34

Section 5-Company's Recent Developments 35

Sep 15, 2015: Newron Reports Half-Year 2015 Results 35

Mar 04, 2015: Newron Pharmaceuticals Reports 2014 Financial Results 37

Section 6-Appendix 38

Methodology 38

Ratio Definitions 38

About GlobalData 42

Contact Us 42

Disclaimer 42

List of Figures

Newron Pharmaceuticals S.p.A., Pipeline Products by Therapy Area 10

Newron Pharmaceuticals S.p.A., Pipeline Products by Development Phase 11

Newron Pharmaceuticals S.p.A., Performance Chart (2011-2015) 29

Newron Pharmaceuticals S.p.A., Ratio Charts 31

Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 32

Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 33

List of Tables

Newron Pharmaceuticals S.p.A., Key Facts 6

Newron Pharmaceuticals S.p.A., Key Employees 7

Newron Pharmaceuticals S.p.A., Key Employee Biographies 8

Newron Pharmaceuticals S.p.A., Major Products and Services 9

Newron Pharmaceuticals S.p.A., Number of Pipeline Products by Therapy Area 10

Newron Pharmaceuticals S.p.A., Number of Pipeline Products by Development Stage 11

Newron Pharmaceuticals S.p.A., Pipeline Products By Therapy Area and Development Phase 12

Newron Pharmaceuticals S.p.A., History 13

Newron Pharmaceuticals S.p.A., Subsidiaries 19

Newron Pharmaceuticals S.p.A., Key Competitors 26

Newron Pharmaceuticals S.p.A., Ratios based on current share price 27

Newron Pharmaceuticals S.p.A., Annual Ratios 28

Newron Pharmaceuticals S.p.A., Interim Ratios 30

Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 32

Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 33

Newron Pharmaceuticals S.p.A., Recent Deals Summary 34

Currency Codes 38

Capital Market Ratios 38

Equity Ratios 39

Profitability Ratios 39

Cost Ratios 40

Liquidity Ratios 40

Leverage Ratios 41

Efficiency Ratios 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

PharmEste

Pharmaleads SA

Neuronax SAS

Domain Therapeutics SA

Neurocrine Biosciences, Inc.

Newron Pharmaceuticals S.p.A., SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license

Single User License
USD 125 INR 8131
Site License
USD 250 INR 16263
Corporate User License
USD 375 INR 24394

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com